Alnylam Pharmaceuticals
Makes Onpattro, an RNA medicine that reaches the liver inside a lipid nanoparticle.
BioPharm International, 13 Aug 2018Prices by TradingView, about 15 minutes delayed. Not investment advice.
- Ticker
- ALNY · Nasdaq
- Based in
- United States
- Website
- alnylam.com ↗
How nano is it?
No filing of theirs says yet
We flag how much of a business is nanotechnology only when the company's own filings say it. Until then we describe what it makes.
What we track
Its technologies, and how far each has got
On the record
Latest steps
The newest dated events on the technologies above.
- Approval
Onpattro
The FDA approved Onpattro, a first-of-its-kind RNA-based medicine, for nerve damage caused by hereditary ATTR amyloidosis in adults.
BioPharm International, 13 Aug 2018
Not investment advice. We describe what companies do and what their own filings say; we never say whether to buy or sell.